[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adenosine-triphosphate-activities\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adenosine-triphosphate-activities":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100338382","genotype--phenotype-correlation-of-pklr-variants-with-pyruvate-kinase-23-diphosphglycerate-and-adenosine-triphosphate-activities-in-red-blood-cells-of-people-with-sickle-cell-disease-100338382",false,"NCT03685721","Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease","Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients With Sickle Cell Disease","* INCLUSUION CRITERIA:\n* Between 18 and 80 years of age\n* African or of African descent\n* Capacity to consent is required\n\nEXCLUSION CRITERIA:\n\n* Self-reported history of blood transfusion within the last 8 weeks\n* Known to have pyruvate kinase deficiency and be on AG348\n* All volunteers will undergo the consent process under this protocol to allow for eligibility assessment. Once they have been consented to participate, they will undergo procedures per Protocol.",true,"ALL","18 Years","80 Years",{"count":21,"type":22},800,"ESTIMATED","OBSERVATIONAL","Background:\n\nSome people with the same disorder on a genetic level have more complications than others. Researchers want to look for a link between the PKLR gene and sickle cell disease (SCD) symptoms. The PKLR gene helps create a protein, called pyruvate kinase that is essential in normal functioning of the red blood cell. Differences in the PKLR gene, called genetic variants, may cause some changes in the pyruvate kinase protein and other proteins, that can affect functioning of the red blood cell adding to the effect of SCD. Researchers can study these differences by looking at DNA (the material that determines inherited characteristics).\n\nObjective:\n\nTo study how the PKLR gene affects sickle cell disease.\n\nEligibility:\n\nAdults ages 18-80 of African descent. They may have sickle cell disease or not. They must not have had a transfusion recently or have a known deficiency of pyruvate kinase. They cannot be pregnant.\n\nDesign:\n\nParticipants will be screened with questions.\n\nParticipants will have blood drawn by needle in an arm vein. The blood will be genetically tested. Not much is known about how genes affect SCD, so the test results will not be shared with participants or their doctors.\n\n...",[26,27,28],"Sickle Cell","PKLR Variants","Adenosine Triphosphate Activities",[30,31,32,33,34],"ATP","Trait","GDP","Genetics","Natural History","RECRUITING","2026-06-05",{"date":38,"type":39},"2026-06-08","ACTUAL",{"date":41,"type":39},"2018-10-11",{"date":43,"type":22},"2026-07-01",{"name":45,"class":46},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":47},"100610183","early-phase-1-effect-of-terazosin-on-atp-levels-in-people-with-amyotrophic-lateral-sclerosis-100610183","NCT07224269","Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis","A Pilot Study of the Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis","TZ-ALS","INCLUSION CRITERIA\n\n* Ages 18 - 80 years old\n* Diagnosed with ALS based on Gold Coast Criteria\n* ALS symptom onset within 36 months at enrollment\n* Slow vital capacity (SVC) \\> 65%\n* Riluzole use-Never taken or taking a stable dose for at least 4 weeks prior to screening visit or will refrain from starting for the duration of the study\n* Edaravone use-Never taken or completed at least one cycle (typically 14 days) prior to screening visit or will refrain from starting for the duration of the study\n* Must have the ability to swallow pills at the time of the screening visit, and in the principle investigator's opinion, have the ability to swallow pills for the duration of the study\n* Willing to use highly effective contraception for the duration of the trial treatment and for a duration of 80 days after the last dose.\n\nEXCLUSION CRITERIA\n\n* Orthostatic hypotension at screening is defined as decrease in BP \\> 20 mmHg systolic or \\> 10 mmHg diastolic and HR increase \\\u003C20 bpm on transition from supine to sitting or from sitting to standing\n* Known allergy or previous adverse reaction to terazosin or related compound\n* Current use of terazosin or concurrent use of doxazosin, alfuzosin, prazosin, or tamsulosin at the time of screening visit or within the 3 months prior to baseline visit\n* Pregnancy or breastfeeding women\n* Taking therapeutic anticoagulant medication (i.e. warfarin, DOAC's, full dose Lovenox or heparin)\n* Liver function blood tests (ALT or AST) more than twice the upper limit of normal\n* Hemoglobin \\\u003C 11.0 g\u002FdL\n* Traumatic brain injury or post-traumatic stress disorder\n* Presence of a confounding acute or unstable medical, psychiatric, or orthopedic condition\n* Noncompliant or sporadic use of medications that modulate the central nervous system\n* Uncontrolled major depression or bipolar affective disorder, or other mental health disorders that are, in the opinion of the PI, sufficiently severe to increase risk of experiencing an Adverse Drug Reaction (ADR)\n* Current suicidal ideation as measured by question 2 of the Columbia-Suicide Severity Rating Scale (C-SSRS)\n* Participants with insufficient decisional capacity to provide written informed consent determined by the primary investigator.\n* Noncompliant or sporadic use of antihypertensive medications\n* Unable to lie supine and still for 60 minutes for the duration of the study\n* Currently taking part in another clinical trial with an investigational medicinal product or having taken part in one in the three months prior to screening visit\n* Current diagnosis of diabetes (type 1 or type 2) or healthcare professional-recommended treatment (medication, exercise or diet) of diabetes mellitus\n* Screening visit glucose \\>140 mg\u002Fdl",{"count":57,"type":22},20,"INTERVENTIONAL",[60],"EARLY_PHASE1","This will be a single center, randomized, double-blind, placebo-controlled pilot study to assess the safety and tolerability of terazosin (TZ) at a dose of 5 milligrams (mg) per os (PO) daily for patients with amyotrophic lateral sclerosis (ALS). The primary outcome of this study is to determine whether TZ increases adenosine triphosphate (ATP) levels in ALS. The investigators will measure adverse outcomes, safety, and tolerability of taking TZ. Procedures include blood draws, spirometry, fluorodeoxyglucose-positron emission tomography (FDG-PET) scans, questionnaires, and physical examinations. TZ will be titrated up to 5 mg PO daily. This is a pilot study and is not powered to assess efficacy of this medication. The investigators' hope is that this study will guide future studies of this (and similar) medications for the disease modification of ALS. This study also aims to learn more about how patients produce and use energy and if TZ can help to reverse energy deficits that appear in ALS.",[63,28],"Amyotrophic Lateral Sclerosis",[65,66,67],"amyotrophic lateral sclerosis","terazosin","clinical trial","NOT_YET_RECRUITING","2026-03-06",{"date":71,"type":39},"2026-03-10",{"date":73,"type":22},"2026-05-01",{"date":75,"type":22},"2027-05-31",{"name":77,"class":78},"University of Iowa","OTHER"]